{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:28:39Z","timestamp":1762507719101,"version":"build-2065373602"},"reference-count":39,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,7,3]],"date-time":"2020-07-03T00:00:00Z","timestamp":1593734400000},"content-version":"am","delay-in-days":337,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.jdiacomp.2019.05.001","type":"journal-article","created":{"date-parts":[[2019,5,10]],"date-time":"2019-05-10T11:42:20Z","timestamp":1557488540000},"page":"567-571","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Loop diuretic use among patients with heart failure and type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors"],"prefix":"10.1016","volume":"33","author":[{"given":"Erin R.","family":"Weeda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christy","family":"Cassarly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel L.","family":"Brinton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David W.","family":"Shirley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kit N.","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2019.05.001_bb0005","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0002-9149(74)90089-7","article-title":"Role of diabetes in congestive heart failure: the Framingham study","volume":"34","author":"Kannel","year":"1974","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jdiacomp.2019.05.001_bb0010","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2019.05.001_bb0015","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl JMed"},{"key":"10.1016\/j.jdiacomp.2019.05.001_bb0020","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","author":"Wiviott","year":"2019","journal-title":"N Engl J Med. 380."},{"key":"10.1016\/j.jdiacomp.2019.05.001_bb0025","unstructured":"Boehringer Ingelheim. EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced). Available from: https:\/\/www.dovepress.com\/author_guidelines.php?content_id=2967"},{"key":"10.1016\/j.jdiacomp.2019.05.001_bb0030","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/1074248413497257","article-title":"Diuretics: a review and update","volume":"19","author":"Roush","year":"2014","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.jdiacomp.2019.05.001_bb0035","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"62","author":"Yancy","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jdiacomp.2019.05.001_bb0040","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1253\/circj.CJ-16-0780","article-title":"Diuretic action of sodium-glucose cotransporter 2 inhibitors and its importance in the management of heart failure","volume":"80","author":"Kimura","year":"2016","journal-title":"Circ J"},{"key":"10.1016\/j.jdiacomp.2019.05.001_bb0045","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.2337\/dc19-Srev01","article-title":"Summary of revisions: standards of medical care in diabetes \u2013 2019","volume":"42","author":"American Diabetes Association","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2019.05.001_bb0050","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"key":"10.1016\/j.jdiacomp.2019.05.001_bb0055","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"year":"2011","series-title":"Bridgewater","author":"Lasix [package insert]","key":"10.1016\/j.jdiacomp.2019.05.001_bb0060"},{"year":"2008","series-title":"Parsippany","author":"Bumex [package insert]","key":"10.1016\/j.jdiacomp.2019.05.001_bb0065"},{"year":"2012","series-title":"Somerset","author":"Demadex [package insert]","key":"10.1016\/j.jdiacomp.2019.05.001_bb0070"},{"year":"2014","series-title":"Parsippany","author":"Edecrin [package insert]","key":"10.1016\/j.jdiacomp.2019.05.001_bb0075"},{"key":"10.1016\/j.jdiacomp.2019.05.001_bb0080","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/ejhf.235","article-title":"Loop diuretic dose adjustments after a hospitalization for heart failure: insights from ASCEND-HF","volume":"17","author":"Devore","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jdiacomp.2019.05.001_bb0085","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1093\/eurheartj\/ehv728","article-title":"Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME trial","volume":"37","author":"Fitchett","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jdiacomp.2019.05.001_bb0090","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1161\/CIRCULATIONAHA.118.034222","article-title":"Canagliflozin and heart failure in type 2 diabetes mellitus: results from the CANVAS program (Canagliflozin Cardiovascular Assessment Study)","volume":"138","author":"R\u00e5dholm","year":"2018","journal-title":"Circulation."},{"key":"10.1016\/j.jdiacomp.2019.05.001_bb0095","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1161\/CIRCULATIONAHA.117.029190","volume":"136","author":"Kosiborod","year":"2017","journal-title":"Circulation."},{"key":"10.1016\/j.jdiacomp.2019.05.001_bb0100","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11936-017-0522-x","article-title":"Promise of SGLT2 inhibitors in heart failure: diabetes and beyond","volume":"19","author":"Martens","year":"2017","journal-title":"Curr Treat Options Cardiovasc Med"},{"key":"10.1016\/j.jdiacomp.2019.05.001_bb0105","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes: cardiovascular and kidney effects, potential mechanisms and clinical applications","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation."},{"key":"10.1016\/j.jdiacomp.2019.05.001_bb0110","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1161\/CIRCULATIONAHA.117.030012","article-title":"Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials","volume":"136","author":"Lytvyn","year":"2017","journal-title":"Circulation."},{"key":"10.1016\/j.jdiacomp.2019.05.001_bb0115","doi-asserted-by":"crossref","first-page":"825","DOI":"10.7326\/0003-4819-135-9-200111060-00012","article-title":"Clinical inertia","volume":"135","author":"Phillips","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jdiacomp.2019.05.001_bb0120","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1177\/1753944709356012","article-title":"Overcoming clinical inertia to achieve blood pressure goals: the role of fixed-dose combination therapy","volume":"4","author":"Basile","year":"2010","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"10.1016\/j.jdiacomp.2019.05.001_bb0125","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1161\/01.HYP.0000200702.76436.4b","article-title":"Therapeutic inertia is an impediment to achieving the Healthy People 2010 blood pressure control goals","volume":"47","author":"Okonofua","year":"2006","journal-title":"Hypertension."},{"key":"10.1016\/j.jdiacomp.2019.05.001_bb0130","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1093\/eurheartj\/ehi890","article-title":"Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods","volume":"27","author":"Ahmed","year":"2006","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jdiacomp.2019.05.001_bb0135","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1161\/CIRCHEARTFAILURE.108.821785","article-title":"Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil?","volume":"2","author":"Felker","year":"2009","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jdiacomp.2019.05.001_bb0140","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.cardfail.2008.01.015","article-title":"The association between high-dose diuretics and clinical stability in ambulatory chronic heart failure patients","volume":"14","author":"Mielniczuk","year":"2008","journal-title":"J Card Fail"},{"key":"10.1016\/j.jdiacomp.2019.05.001_bb0145","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1161\/01.CIR.82.5.1724","article-title":"Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD)","volume":"82","author":"Francis","year":"1990","journal-title":"Circulation."},{"key":"10.1016\/j.jdiacomp.2019.05.001_bb0150","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1093\/eurheartj\/16.suppl_N.65","article-title":"Neurohormonal activation and congestive heart failure: today's experience with ACE inhibitors and rationale for their use","volume":"16","author":"Sigurdsson","year":"1995","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jdiacomp.2019.05.001_bb0155","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/eurheartj\/17.suppl_B.21","article-title":"Beta-blockade in the management of chronic heart failure. Another step in the conceptual evolution of a neurohormonal model of the disease","volume":"17","author":"Packer","year":"1996","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jdiacomp.2019.05.001_bb0160","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/hrt.57.1.17","article-title":"Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics","volume":"57","author":"Bayliss","year":"1987","journal-title":"Br Heart J"},{"key":"10.1016\/j.jdiacomp.2019.05.001_bb0165","article-title":"Validity of heart failure diagnoses in administrative databases: a systematic review and meta-analysis","volume":"9","author":"Mccormick","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.jdiacomp.2019.05.001_bb0170","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1161\/CIRCHEARTFAILURE.108.772228","article-title":"Heart failure care in the outpatient cardiology practice setting: findings from IMPROVE HF","volume":"1","author":"Fonarow","year":"2008","journal-title":"Circ Heart Fail"},{"year":"2013","series-title":"Titusville","author":"Invokana [Package Insert]","key":"10.1016\/j.jdiacomp.2019.05.001_bb0175"},{"year":"2014","series-title":"Princeton","author":"Farxiga [Package Insert]","key":"10.1016\/j.jdiacomp.2019.05.001_bb0180"},{"year":"2016","series-title":"Ridgefield","author":"Jardiance [Package Insert]","key":"10.1016\/j.jdiacomp.2019.05.001_bb0185"},{"year":"2019","series-title":"Research Triangle Park","author":"Avandia [Package Insert]","key":"10.1016\/j.jdiacomp.2019.05.001_bb0190"},{"year":"2011","series-title":"Deerfield","author":"Actos [Package Insert]","key":"10.1016\/j.jdiacomp.2019.05.001_bb0195"}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872719302454?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872719302454?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:08:39Z","timestamp":1761005319000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872719302454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S1056872719302454"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2019.05.001","relation":{},"ISSN":["1056-8727"],"issn-type":[{"type":"print","value":"1056-8727"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Loop diuretic use among patients with heart failure and type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2019.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}